Lattice Medical Raises 43m Post Cancer Reconstruction

Lattice Medical raises €43 million to transform post-cancer reconstruction

October 29, 2025

Lille, France, October 23, 2025 – LATTICE MEDICAL, a French Medtech company specializing in tissue engineering, announces a Series B fundraising round of €43 million,…

Latest News

Lattice Medical Raises 43m Post Cancer Reconstruction

Lattice Medical raises €43 million to transform post-cancer reconstruction

October 29, 2025

Treos Bio Phase Ii Clinical Trial Mss Colorectal Cancer

TREOS Bio Partners with Charité Berlin and Junshi Biosciences to Launch Pivotal Phase II Clinical Trial in Refractory MSS Colorectal Cancer

August 27, 2025

Vaxxas Hd Map A90m Funding

Vaxxas secures ~A$90 million in funding to commercialise needle-free vaccination delivery technology

August 25, 2025

Doron Therapeutics Positive Phase 2 End Of Phase Meeting 2025

Doron Therapeutics Announces Positive End-of-Phase 2 and Initial RMAT Meeting With FDA for MOTYS (PTP-001) in the Treatment of Knee Osteoarthritis

May 20, 2025

Azalea Vision 9m Series A Intelligent Connected Vision Platform

Azalea Vision Raises €9 Million in First Closing of Series A to Further Develop Intelligent Connected Vision Platform

April 30, 2025

Cadwell Seer Investment Epilepsy Diagnostics 2025

Cadwell Makes a Strategic Investment in Seer Medical to Expand Home-Based Epilepsy Diagnostics

April 16, 2025

Sprim Oneim 300m Joint Venture Clinical Trial Financing 2025

R&D SERVICES/CRO

SPRIM Global Investments and OneIM Announce $300mn Joint Venture to Accelerate Clinical Trial Financing

March 11, 2025

Pulsesight Series A Financing Pst 611 Dry Amd 2025 1

PulseSight Therapeutics Announces First Close of its Series A Financing to Fund Clinical Development of PST-611 in dry AMD

February 13, 2025

Obviohealth Obviogo 2.2 Ai Driven Study Management 2025

DIGITAL CLINICAL SOLUTION

ObvioHealth Introduces ObvioGo 2.2: Transforming Study Management with AI-Driven Innovation

January 17, 2025

Rheumagen Series A Financing Hla Gene Editing Therapies 2024 1

RheumaGen, Inc. Launches with $15 Million Series A Financing to Advance a New Class of HLA Gene-Editing Therapies for Major Autoimmune Diseases

January 9, 2025

Cilcare Completes 40m Series A

Cilcare completes a €40M series A

December 5, 2024

Doron Therapeutics 11m Series A Osteoporosis Drug Phase 3 Clinical Study

Doron Therapeutics Raises $11M Series A to Progress Biologic Regenerative Osteoarthritis Drug into Phase 3 Clinical Studies

November 25, 2024

Napo Therapeutics Best Pharmaceuticals Innovator Europe 2024

Jaguar Health Family Company Napo Therapeutics Named “Best Pharmaceuticals Innovator of the Year – Europe”

November 19, 2024

Obviohealth Richard Watkins Chief Revenue Officer Transformation

ObvioHealth Welcomes Richard Watkins as Chief Revenue Officer at a Pivotal Moment of Transformation

October 16, 2024

Obviohealth Appointment Nicholas Campbell 2024

DIGITAL CLINICAL SOLUTION

ObvioHealth Announces the Appointment of Nicholas Campbell to Its Board of Directors

October 10, 2024

Pulsesight Therapeutics Presents Pst 611 Ever Congress 2024

PulseSight Therapeutics to Present Data on PST-611 at EVER Congress 2024

October 7, 2024

Novel Validated Approach Monitoring Infant Growth Home Clinical Trials

R&D SERVICES/CRO

SPRIM PRO Announces a Novel and Validated Approach for Monitoring Infant Growth from Home in Clinical Trials, Reducing Burdens on Caregivers and Clinical Sites

September 24, 2024

Obviohealth Strategic Investment By Guardant Health

DIGITAL CLINICAL SOLUTION

ObvioHealth announces strategic investment by Guardant Health to accelerate deployment of oncology clinical trials globally

July 29, 2024

Mimi Tang Prota Therapeutics Forbes Australia

Forbes Australia recognizes Prota Therapeutics for making waves in Australia’s startup scene at the moment

June 24, 2024

Biosenic On Its Way To Find The Necessary Funds To Perform Its Key Clinical Trial On Chronic Graft Versus Host Disease

Prota Therapeutics US $21 Million Financing Led by SPRIM Global Investments

January 16, 2024

Spexis Provides Update Regarding Debt Restructuring Moratorium

Stalicla Secures $17.4 Million in Series B Financing

January 16, 2024

Regask Welcomes New Chief Product & Technology Officer

DIGITAL CLINICAL SOLUTION

RegASK Welcomes New Chief Product & Technology Officer

November 2, 2023

Obviohealth Strengthens Leadership Team With Key Industry Appointments

DIGITAL CLINICAL SOLUTION

ObvioHealth Strengthens Leadership Team with Key Industry Appointments

October 17, 2023

Fibronostics Announces Partnership With Stone Diagnostics

Fibronostics Announces Partnership with Stone Diagnostics

October 10, 2023

Spexis Provides Business Update And Announces Financial Results For The First Half Of 2023

Spexis provides business update and announces financial results for the first half of 2023

September 29, 2023

Spexis Announces Usd $2.5 Million Capital Commitment To Support The Upcoming Phase 3 Colifin® Studies

Spexis announces USD $2.5 million capital commitment to support the upcoming Phase 3 ColiFin® studies

August 14, 2023

Readout Ai Secures Pre Seed Funding To Decrease The Time From Clinical Trial Data To Clinical Trial Insight

DIGITAL CLINICAL SOLUTION

Readout AI Secures Pre-Seed Funding to Decrease the Time from Clinical Trial Data to Clinical Trial Insight

July 14, 2023

Sprim Global Investments Pte. Ltd. Completes Equity Investment In Uk Specialist Clinical Trial Site, Vctc Ltd.

DIGITAL CLINICAL SOLUTION

SPRIM Global Investments Pte. Ltd. completes equity investment in UK specialist clinical trial site, VCTC Ltd.

May 26, 2023

Obviohealth Signs R&d Partnership With A Star To Identify And Develop Novel Digital Biomarkers

DIGITAL CLINICAL SOLUTION

ObvioHealth Signs R&D Partnership with A*STAR to Identify and Develop Novel Digital Biomarkers

May 3, 2023

Spexis Announces Closing Of Capital Commitment Of Usd 4.5 Million From Sprim Global Investments (sgi) To Enable Initiation Of Colifin® Phase 3 Study

Spexis announces closing of capital commitment of USD 4.5 million from SPRIM Global Investments (SGI) to enable initiation of ColiFin® Phase 3 study

April 18, 2023

Data Vantage | Aum Biosciences, Scg Cell Therapy, Blood And Hello Health Disclose Updates

AUM Biosciences, SCG Cell Therapy, Blood And Hello Health Disclose Updates

April 6, 2023

1nhealth Launches Site Advisory Board To Prioritize Site Voice

DIGITAL CLINICAL SOLUTION

1nHealth Launches Site Advisory Board to Prioritize Site Voice

March 28, 2023

Stalicla And Firefly Neuroscience Enter Partnership Agreement For The Development Of Electroencephalogram (eeg) As A Biomarker For Subgroups Of Patients With Asd

STALICLA and Firefly Neuroscience enter Partnership Agreement for the Development of Electroencephalogram (EEG) as a Biomarker for Subgroups of Patients with ASD

March 27, 2023

Obviohealth To Conduct A Pioneering Decentralized Clinical Trial On The Mi Helper Device For Treatment Of Migraine

DIGITAL CLINICAL SOLUTION

ObvioHealth to Conduct a Pioneering Decentralized Clinical Trial on The Mi-Helper Device for Treatment of Migraine

March 16, 2023

Jaguar Health Announces Initial Close In Private Placement Financing Round For Napo Therapeutics S.p.a.

Jaguar Health Announces Initial Close in Private Placement Financing Round for Napo Therapeutics S.p.A.

February 9, 2023

Spexis And Sprim Global Investments (sgi) Announce Plans For Clinical Trial Partnership To Fund Up To Half Of The Projected Phase 3 Clinical Development Costs Of Colifin®

Spexis and SPRIM Global Investments (SGI) Announce Plans for Clinical Trial Partnership to Fund up to Half of the Projected Phase 3 Clinical Development Costs of ColiFin®

February 8, 2023

Stalicla Signs Exclusive In Licensing Agreement For Late Stage Clinical Neuropsychiatric And Neurodevelopmental Disorder Treatment

STALICLA signs exclusive in-licensing agreement for late-stage clinical neuropsychiatric and neurodevelopmental disorder treatment

January 9, 2023

Regask Announces Us$10m Series A Funding Round Led By Monograph Capital To Accelerate Its Growth

DIGITAL CLINICAL SOLUTION

RegASK announces US$10m Series A Funding Round led by Monograph Capital to accelerate its growth

December 15, 2022

Aum Biosciences, A Global Biotechnology Company Developing Precision Oncology Therapeutics, Announces Plans To Become A Public Company Via Merger With Mountain Crest Acquisition Corp. V

AUM Biosciences, a Global Biotechnology Company Developing Precision Oncology Therapeutics, Announces Plans to Become a Public Company via Merger with Mountain Crest Acquisition Corp. V

October 20, 2022

Stalicla Sa And Evgen Pharma Plc Ink $160.5m Licensingdeal For Sfx 01

Stalicla SA and Evgen Pharma plc ink $160.5m licensing deal for SFX-01

October 12, 2022

Obviohealth Introduces Obviogo Next Generation Dct Platform Mobile Application Delivering Stronger Evidence

DIGITAL CLINICAL SOLUTION

ObvioHealth Introduces ObvioGo™, a Next-Generation DCT Platform and Mobile Application Delivering Stronger Evidence

September 14, 2022

Aum Biosciences Receives Fda Orphan Drug Designation For Aum601 For The Treatment Of Solid Tumors With The Ntrk Fusion Gene

AUM Biosciences Receives FDA Orphan Drug Designation for AUM601 for the Treatment of Solid Tumors with the NTRK Fusion Gene

August 18, 2022

Obviohealth Ranked On Inc. 5000's List Of Fastest Growing Private Companies For Second Consecutive Year

DIGITAL CLINICAL SOLUTION

ObvioHealth Ranked on Inc. 5000’s List of Fastest Growing Private Companies for Second Consecutive Year

August 16, 2022

Treos Bio Announces First Patient Dosed In Phase 2 Trial Of Polypepi1018 In Combination With Roche’s Pd L1 Inhibitor For The Treatment Of Metastatic Colorectal Cancer

Treos Bio Announces First Patient Dosed in Phase 2 Trial of PolyPEPI1018 in Combination with Roche’s PD-L1-Inhibitor for the Treatment of Metastatic Colorectal Cancer

June 27, 2022

Fibronostics Secures Financing, Announces New Ceo

Fibronostics Secures Financing, Announces New CEO

June 15, 2022

Liverfast Can Be Better Than The Gold Standard Liver Biopsy, Because It Can Predict Mortality And Morbidity Of Patients.

DIGITAL CLINICAL SOLUTION

LIVERFASt can be better than the gold standard liver biopsy, because it can predict mortality and morbidity of patients.

April 2, 2022

DIGITAL CLINICAL SOLUTION

Faster, safer, more accurate trials.

March 5, 2022

Sprim Global Investments Names Susan Dallabrida As Chief Executive Officer Of Sprim Consultancy

R&D SERVICES/CRO

SPRIM Global Investments names Susan Dallabrida as Chief Executive Officer of SPRIM Consultancy

February 8, 2022

Digital Heath 150 2021

DIGITAL CLINICAL SOLUTION

The Digital Health 150: The Top Digital Health Companies Of 2021

December 8, 2021

GHO Capital Acquires Genesis Research, a Pioneer in Tech-enabled Real-World Evidence and HEOR Services

November 16, 2021

This site uses cookies to offer you a better browsing experience. By browsing this website, you agree to our use of cookies.

Accept